News
-
-
PRESS RELEASE
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Formycon AG publishes preliminary figures for 2023 financial year and guidance for 2024. EBITDA expected around EUR 1.5 million for 2023 and revenues of EUR 55-65 million for 2024 -
-
PRESS RELEASE
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada and Switzerland, expanding availability in 17 countries. Biosimilar offers cost-effective treatment for retinal diseases -
-
PRESS RELEASE
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options -
-
-
PRESS RELEASE
Gedeon Richter becomes strategic investor of Formycon via equity investment
Formycon AG announces strategic investment from Gedeon Richter, leading to a 9.08% equity takeover via cash capital increase of EUR 82.84 million. The investment will ensure high development pace and operational progress -
PRESS RELEASE
EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
Formycon AG resolves on EUR 82.84 million cash capital increase by issuing 1,603,877 new shares, all subscribed by Gedeon Richter as strategic investor. Proceeds for biosimilar pipeline development. New shares to be traded on Frankfurt Stock Exchange
![Accesswire](/assets/images/accesswire-inline.png)
-
Robust Intelligence Partners With Pinecone to Secure Retrieval-Augmented Generation (RAG) AI Applications
-
Boron One Announces Successful Closing of Early Warrant Exercise Incentive Program
-
Eagle Plains Announces Conditional Approval of Warrant Expiry Extension
-
Goldflare Announces Changes in Leadership
-
Gina Corena & Associates Participates in 2024 Nevada Justice Association Annual Summer Gala This Weekend
![EQS Group](/assets/images/eqs-group.png)
-
EQS-Adhoc: VOLKSWAGEN AKTIENGESELLSCHAFT: Volkswagen AG resolves on investment by Volkswagen of initially 1 billion USD in Rivian Automotive, Inc., and intends to establish a joint venture
-
CompuGroup Medical strengthens market position in Northern Europe with the acquisition of Norwegian Pridok
-
EQS-Adhoc: CompuGroup Medical SE & Co. KGaA: CompuGroup Medical acquires Pridok AS
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
Annual General Meeting 2024 of Meyer Burger approves all motions
![Les Echos](/assets/images/les-echos.png)
-
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
-
Schneider Electric announces the reference share price and the initial conversion/exchange ratio of its new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 and the results of the repurchase of the OCEANEs
-
FREY signs new financing for €400m
-
Schneider Electric announces the success of its offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million
-
Cie du Bois Sauvage: Buy back of own shares – week from 17/06/2024 to 21/06/2024